Selank

Overview

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, built by appending a stabilising proline-glycine-proline tripeptide to the C-terminus of tuftsin, a naturally occurring immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) first characterised in the 1970s as a fragment released from the heavy chain of immunoglobulin G. It was developed during the late 1980s and 1990s by researchers working in the same institutional lineage as Ivan Ashmarin's ACTH-fragment programme at Moscow State University and the Institute of Molecular Genetics of the Russian Academy of Sciences, which makes Selank a close sibling project to Semax rather than an unrelated compound that merely happens to share a research tradition. Both peptides were designed around the same core insight developed within that network: a biologically active but rapidly degraded natural peptide fragment could be stabilised against plasma peptidases by appending Pro-Gly-Pro to its C-terminus, extending its functional persistence without introducing new receptor pharmacology of its own. The laboratory code TP-7 is still occasionally used in older Russian sources and in some research-chemical listings, though Selank is the name under which the compound is registered and marketed.

Tuftsin itself was originally studied from the 1970s onward for its effects on phagocytic activity and immune cell function, most notably its capacity to stimulate the phagocytic and migratory behaviour of neutrophils and macrophages, and it attracted interest as a potential immunostimulant in conditions of impaired host defence. In its native form, however, tuftsin is degraded within minutes in circulation by aminopeptidases and other proteases, which sharply limited its pharmacological usefulness despite promising early immunological findings and meant that any therapeutic application would have required either continuous infusion or a chemically stabilised analogue. The Russian research group's proposal, following the precedent set by the Ashmarin group's work on ACTH(4-10), was that a Pro-Gly-Pro-stabilised tuftsin analogue might retain useful immunomodulatory activity while also revealing central nervous system effects relevant to stress and anxiety that had not been apparent in the native, rapidly degraded peptide. This built on a broader Soviet-era pattern of investigating small endogenous peptide fragments for behavioural and neurotropic activity distinct from the physiological role under which they were first described.

The resulting compound, Selank, was subsequently characterised primarily for its effects on anxiety-related behaviour in animal models and, later, in Russian clinical populations, rather than for immune modulation as such, even though some tuftsin-like immunostimulatory activity has been reported to persist in pharmacological testing. This shift in emphasis from an immunopeptide analogue toward a centrally acting anxiolytic candidate mirrors, in a different domain, the same reframing that occurred with Semax: a peptide designed around stabilising a known natural fragment ended up being developed and marketed chiefly for a CNS indication that was not the original fragment's best-known physiological role.

As with Semax, oral bioavailability of a peptide of this size is negligible, and the Russian development programme settled on intranasal administration as the primary delivery route, favouring direct or near-direct access from the nasal mucosa toward the central nervous system while reducing systemic peptidase exposure relative to oral dosing. This shared design logic, shared institutional lineage, and shared delivery strategy is why Selank and Semax are so often discussed as a pair in both the Russian pharmacological literature and the international nootropic-research community, even though their proposed indications diverge: Semax's Russian registration centres on stroke rehabilitation and cognitive disorders, while Selank's centres on anxiety and adaptive-stress conditions. The two compounds are frequently manufactured by the same Russian pharmaceutical producers, sold in similar intranasal-solution packaging, and discussed in the same online communities, which has tended to blur, in popular discussion, the distinction between their separate evidence bases and indications.

Selank was subsequently registered as a medicine in Russia, marketed as an intranasal solution, for generalised anxiety disorder and related adaptive-stress conditions, and has been promoted there as an anxiolytic without the sedation, cognitive blunting or dependence potential associated with benzodiazepine-class drugs. These are claims made within the Russian regulatory and marketing context rather than conclusions independently verified by MHRA-, EMA- or FDA-standard trials, and readers should treat them as such rather than as settled international consensus. This page summarises what has been published on Selank's proposed mechanisms, its research and regulatory history, the available safety information, and how the compound is treated under UK law. Nothing here is medical advice, and the material is intended for research and educational purposes only.

Mechanism of action

Selank's proposed anxiolytic mechanism is presented in the Russian pharmacological literature as fundamentally different from that of benzodiazepines. Rather than acting as a direct positive allosteric modulator at the GABA-A receptor benzodiazepine-binding site, Selank is described as modulating GABAergic tone indirectly, through effects on the expression and turnover of GABA-related signalling components rather than through direct receptor agonism. This distinction is central to how the compound has been marketed in Russia: an anxiolytic effect achieved without occupying the same receptor site responsible for benzodiazepine sedation, tolerance and dependence, though the precise molecular intermediary connecting Selank exposure to altered GABAergic function has not been isolated with the same clarity as a defined receptor-ligand interaction would provide. Some Russian pharmacology reviews have proposed that Selank's peptide fragments, generated during its own metabolic breakdown, may themselves contribute biological activity relevant to this GABAergic effect, an idea that echoes similar 'active metabolite' proposals made for Semax and for other Pro-Gly-Pro-stabilised peptides from the same research tradition, though this remains a hypothesis rather than a demonstrated mechanism.

A second and frequently cited mechanistic strand concerns enkephalin metabolism. Selank has been reported to inhibit enkephalin-degrading enzymes, including neutral endopeptidase and aminopeptidase N, thereby prolonging the activity of endogenous enkephalins at opioid receptors. Because enkephalinergic signalling is implicated in stress modulation, pain processing and mood regulation, this proposed effect on peptidase activity has been used to help explain reported anxiolytic and mood-related outcomes without invoking direct receptor binding by Selank itself. This mechanism, if correct, would place Selank in an unusual pharmacological category: an indirect enhancer of an endogenous opioid-peptide tone rather than a receptor agonist or antagonist in its own right, comparable in logic (though not in target) to how certain analgesics act by inhibiting the enzymes that degrade endogenous opioid peptides rather than by binding opioid receptors directly. Independent biochemical confirmation of the specific enzyme-inhibition constants involved remains limited outside the originating Russian research groups, and the relative contribution of this enkephalin-sparing effect compared with the proposed GABAergic and monoaminergic mechanisms has not been quantified.

Monoaminergic effects have also been reported, in a manner that parallels the Semax literature from the same research tradition. Russian pharmacological studies describe Selank-associated changes in serotonergic and noradrenergic turnover in specific brain regions, alongside effects on monoamine oxidase activity, which have been used to rationalise both the anxiolytic profile and reported effects on mood and cognitive performance under stress. Some of this work has also examined dopaminergic pathway activity, reporting altered dopamine turnover in regions associated with reward and motivation, which has been proposed as a partial explanation for reported effects on motivation and subjective wellbeing in addition to anxiolysis proper. As with Semax, this is not presented as classical receptor agonism but as an upstream modulatory influence on monoaminergic systems, and the precise molecular target linking Selank to these downstream monoamine changes has not been definitively established, nor has the temporal sequence connecting peptide administration, enzyme or receptor-level changes, and eventual behavioural outcome been fully mapped.

A further and somewhat unusual claim in the Selank literature concerns brain-derived neurotrophic factor. Several studies from the Russian research groups working on Selank report that its anxiolytic and stress-protective behavioural effects are associated with, and in some experimental designs appear dependent on, changes in hippocampal BDNF expression, mirroring the neurotrophic mechanism proposed for Semax. This BDNF-dependent framing of anxiolysis is less conventional than the GABAergic and enkephalinergic strands of the mechanism, since most established anxiolytic drug classes act through comparatively fast synaptic mechanisms rather than through neurotrophic gene expression that typically develops over hours to days, and the BDNF-anxiolysis link for Selank should be regarded as a preliminary and mechanistically distinctive hypothesis rather than settled pharmacology. If this BDNF-dependent pathway is genuinely important to Selank's anxiolytic effect, it would also help explain reports of effects on stress resilience and adaptive capacity that outlast the peptide's short plasma half-life, since transcriptional and neurotrophic changes are expected to persist well beyond the clearance of circulating peptide.

Taken together, the mechanistic picture presented for Selank is, like that of Semax, diffuse and multi-system rather than centred on a single well-characterised receptor: proposed effects span indirect GABAergic modulation, enkephalinase inhibition, monoaminergic and dopaminergic turnover, and BDNF-linked neurotrophic signalling, with no single pathway established as necessary or sufficient for the anxiolytic phenotype reported in animal and human studies. This breadth is both a source of converging preclinical support, in that multiple independent lines of evidence point toward a genuine biological effect rather than an artefact of a single assay, and a limitation, in that a mechanism this diffuse is considerably harder to pin down, quantify and independently falsify than a single well-defined receptor interaction of the kind used to characterise conventional anxiolytic drug classes.

Research history

Selank emerged from the same broad Russian peptide-research programme that produced Semax, developed from the late 1980s through the 1990s by researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences, building on the tuftsin immunopeptide literature of the 1970s and the Pro-Gly-Pro stabilisation strategy pioneered in the ACTH-fragment work. Where Semax's design target was the neurotropic ACTH(4-10) fragment, Selank's design target was tuftsin, and the two development efforts proceeded in parallel within the same institutional network, sharing methodology, some personnel, and eventually a shared reputation as a linked pair of Russian intranasal neuropeptides. Early pharmacological characterisation through the 1990s established the broad behavioural and biochemical profile that later clinical work would build on: anxiolytic-like effects in standard rodent behavioural assays, a favourable comparison against benzodiazepine reference compounds on measures of sedation and motor function, and the enzyme-inhibition and monoamine-turnover findings that would later be folded into the compound's proposed mechanism.

Clinical development in Russia focused on generalised anxiety disorder and adaptation disorders, sometimes described under the broader Russian clinical framing of neurotic and asthenic conditions, with open-label and comparator-controlled studies reporting anxiolytic efficacy comparable to reference benzodiazepine or non-benzodiazepine anxiolytics in some series, alongside a more favourable profile on measures of sedation, cognitive impairment and withdrawal on discontinuation. This clinical programme, led substantially by researchers including Zozulya, Neznamov and colleagues working within Russian psychiatric and neuropharmacological institutes, accumulated over roughly two decades of published case series and comparator trials, predominantly in Russian-language psychiatric and neurological journals. Selank received Russian state registration as a medicine and has been manufactured and marketed there for over two decades, principally as an intranasal solution, under the same pattern of continued clinical use rather than a single pivotal trial that characterises much of the Russian short-peptide literature.

Selank is very often discussed alongside Semax, both because of the shared institutional origin and because the two compounds are frequently marketed, sold and discussed together in the international research-chemical and nootropics community as a matched pair: Semax for cognitive and neuroprotective effects, Selank for anxiolytic and stress-adaptive effects. This pairing is a reasonable reflection of their shared design lineage, but it should not be mistaken for equivalence of evidence quality or indication; the two peptides have distinct, non-interchangeable target claims, distinct proposed mechanisms of action, and separately accumulated (if overlapping) clinical literatures. As with Semax, independent replication of the Selank literature by research groups outside Russia remains limited, much of the foundational clinical material is Russian-language and was generated under a regulatory and publication environment distinct from contemporary MHRA, EMA or FDA expectations, and no trial meeting modern randomised, blinded, pre-registered standards has been conducted or registered for Selank in a Western regulatory jurisdiction.

Viewed by tier, the strongest part of the Selank evidence base is the rodent behavioural pharmacology comparing it against reference anxiolytics such as diazepam, which is reasonably consistent across the published series and spans multiple standard anxiety paradigms. The mechanistic work on enkephalinase inhibition, monoamine turnover and BDNF expression sits at an intermediate tier: plausible, internally consistent within the originating research groups, but drawn from a comparatively narrow set of Russian laboratories and not yet independently replicated using contemporary methodological standards such as pre-registration or blinded outcome assessment. The human clinical literature, despite spanning multiple case series and comparator trials over two decades, sits at the weakest tier in the same sense as the equivalent Semax literature: encouraging and long-standing, but not built on the randomised, placebo-controlled, adequately powered trial designs that would allow confident quantification of effect size by MHRA, EMA or FDA standards. Readers should weight the anxiolytic-efficacy claims for Selank accordingly.

Summarised studies